To elucidate MGAT1’s role in HCC immunotherapy, we incorporated an external cohort for an in-depth analysis of Anti-PD-1/PD-L1 checkpoint inhibitors in HCC contexts. Here, MGAT1 is linked to hepatocellular carcinoma.